{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:37:15Z","timestamp":1793655435385,"version":"4.5.1"},"reference-count":130,"publisher":"Harborside Press, LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>Vulvar cancer is annually diagnosed in an estimated 6,470 individuals and the vast majority are histologically squamous cell carcinomas. Vulvar cancer accounts for 5% to 8% of gynecologic malignancies. Known risk factors for vulvar cancer include increasing age, infection with human papillomavirus, cigarette smoking, inflammatory conditions affecting the vulva, and immunodeficiency. Most vulvar neoplasias are diagnosed at early stages. Rarer histologies exist and include melanoma, extramammary Paget\u2019s disease, Bartholin gland adenocarcinoma, verrucous carcinoma, basal cell carcinoma, and sarcoma. This manuscript discusses recommendations outlined in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for treatments, surveillance, systemic therapy options, and gynecologic survivorship.<\/jats:p>","DOI":"10.6004\/jnccn.2024.0013","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T15:35:08Z","timestamp":1710776108000},"page":"117-135","source":"Crossref","is-referenced-by-count":107,"title":["Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology"],"prefix":"10.6004","volume":"22","author":[{"given":"Nadeem R.","family":"Abu-Rustum","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catheryn M.","family":"Yashar","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Arend","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Barber","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Bradley","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Brooks","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana M.","family":"Campos","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzo","family":"Chino","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Sook","family":"Chon","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Ann","family":"Crispens","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari","family":"Damast","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Fisher","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Frederick","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K.","family":"Gaffney","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Gaillard","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Giuntoli","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Glaser","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Holmes","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke E.","family":"Howitt","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Kendra","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanthi","family":"Lea","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nita","family":"Lee","sequence":"additional","affiliation":[{"name":"The UChicago Medicine Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Mantia-Smaldone","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mariani","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mutch","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Nagel","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Nekhlyudov","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirna","family":"Podoll","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Rodabaugh","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Salani","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Schorge","sequence":"additional","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital\/The University of Tennessee Health Science Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Siedel","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Sisodia","sequence":"additional","affiliation":[{"name":"Mass General Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Soliman","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Ueda","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Urban","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"Wethington","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Wyse","sequence":"additional","affiliation":[{"name":"Patient Advocate"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Zanotti","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"McMillian","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Espinosa","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Gynecol Oncol","first-page":"55","article-title":"Conservative and individualized surgery for early squamous carcinoma of the vulva: the treatment of choice for stage I and II (T1-2N0-1M0) disease","volume":"53","author":"Farias-Eisner R","year":"1994","unstructured":"Farias-Eisner R, Cirisano FD, Grouse D,  Conservative and individualized surgery for early squamous carcinoma of the vulva: the treatment of choice for stage I and II (T1-2N0-1M0) disease. Gynecol Oncol 1994;53:55\u201358."},{"key":"B2","series-title":"Cochrane Database Syst Rev","first-page":"CD002036","article-title":"Surgical interventions for early squamous cell carcinoma of the vulva","volume":"2000","author":"Ansink A","year":"2000","unstructured":"Ansink A, van der Velden J. Surgical interventions for early squamous cell carcinoma of the vulva. Cochrane Database Syst Rev 2000;2000:CD002036."},{"key":"B3","series-title":"Obstet Gynecol","first-page":"155","article-title":"Individualization of treatment for stage I squamous cell vulvar carcinoma","volume":"63","author":"Hacker NF","year":"1984","unstructured":"Hacker NF, Berek JS, Lagasse LD,  Individualization of treatment for stage I squamous cell vulvar carcinoma. Obstet Gynecol 1984;63:155\u2013162."},{"key":"B4","series-title":"Gynecol Oncol","first-page":"215","article-title":"Surgical therapy of T1 and T2 vulvar carcinoma: further experience with radical wide excision and selective inguinal lymphadenectomy","volume":"57","author":"Burke TW","year":"1995","unstructured":"Burke TW, Levenback C, Coleman RL,  Surgical therapy of T1 and T2 vulvar carcinoma: further experience with radical wide excision and selective inguinal lymphadenectomy. Gynecol Oncol 1995;57:215\u2013220."},{"issue":"4","key":"B5","series-title":"Cancer","first-page":"1673","article-title":"Conservative management of early vulvar cancer","volume":"71","author":"Hacker NF","year":"1993","unstructured":"Hacker NF, van der Velden J. Conservative management of early vulvar cancer. Cancer 1993;71(4 Suppl):1673\u20131677."},{"key":"B6","series-title":"Semin Surg Oncol","first-page":"168","article-title":"Surgical management of vulvar cancer","volume":"17","author":"Morgan MA","year":"1999","unstructured":"Morgan MA, Mikuta JJ. Surgical management of vulvar cancer. Semin Surg Oncol 1999;17:168\u2013172."},{"key":"B7","series-title":"Cancer","first-page":"2331","article-title":"Vulvar carcinoma. The price of less radical surgery","volume":"95","author":"de Hullu JA","year":"2002","unstructured":"de Hullu JA, Hollema H, Lolkema S,  Vulvar carcinoma. The price of less radical surgery. Cancer 2002;95:2331\u20132338."},{"key":"B8","series-title":"Gynecol Oncol","first-page":"309","article-title":"Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva","volume":"38","author":"Heaps JM","year":"1990","unstructured":"Heaps JM, Fu YS, Montz FJ,  Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol 1990;38:309\u2013314."},{"key":"B9","series-title":"Obstet Gynecol","first-page":"1159","article-title":"Local relapse in patients treated for squamous cell vulvar carcinoma: incidence and prognostic value","volume":"100","author":"Rouzier R","year":"2002","unstructured":"Rouzier R, Haddad B, Plantier F,  Local relapse in patients treated for squamous cell vulvar carcinoma: incidence and prognostic value. Obstet Gynecol 2002;100:1159\u20131167."},{"key":"B10","series-title":"Gynecol Oncol","first-page":"636","article-title":"Margin distance and other clinico-pathologic prognostic factors in vulvar carcinoma: a multivariate analysis","volume":"104","author":"Chan JK","year":"2007","unstructured":"Chan JK, Sugiyama V, Pham H,  Margin distance and other clinico-pathologic prognostic factors in vulvar carcinoma: a multivariate analysis. Gynecol Oncol 2007;104:636\u2013641."},{"key":"B11","series-title":"Gynecol Oncol","first-page":"390","article-title":"The treatment of lateral T1 and T2 squamous cell carcinomas of the vulva confined to the labium majus or minus","volume":"104","author":"DeSimone CP","year":"2007","unstructured":"DeSimone CP, Van Ness JS, Cooper AL,  The treatment of lateral T1 and T2 squamous cell carcinomas of the vulva confined to the labium majus or minus. Gynecol Oncol 2007;104:390\u2013395."},{"key":"B12","series-title":"Cochrane Database Syst Rev","first-page":"CD002224","article-title":"Primary groin irradiation versus primary groin surgery for early vulvar cancer","volume":"2011","author":"van der Velden J","year":"2011","unstructured":"van der Velden J, Fons G, Lawrie TA. Primary groin irradiation versus primary groin surgery for early vulvar cancer. Cochrane Database Syst Rev 2011;2011:CD002224."},{"key":"B13","series-title":"Int J Radiat Oncol Biol Phys","first-page":"389","article-title":"Groin dissection versus groin radiation in carcinoma of the vulva: a Gynecologic Oncology Group study","volume":"24","author":"Stehman FB","year":"1992","unstructured":"Stehman FB, Bundy BN, Thomas G,  Groin dissection versus groin radiation in carcinoma of the vulva: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys 1992;24:389\u2013396."},{"key":"B14","series-title":"Int J Oncol","first-page":"1077","article-title":"Prophylactic inguinal-femoral irradiation as an alternative to primary lymphadenectomy in treatment of vulvar carcinoma","volume":"31","author":"Hallak S","year":"2007","unstructured":"Hallak S, Ladi L, Sorbe B. Prophylactic inguinal-femoral irradiation as an alternative to primary lymphadenectomy in treatment of vulvar carcinoma. Int J Oncol 2007;31:1077\u20131085."},{"key":"B15","series-title":"Int J Radiat Oncol Biol Phys","first-page":"963","article-title":"Inguinofemoral radiation of N0,N1 vulvar cancer may be equivalent to lymphadenectomy if proper radiation technique is used","volume":"27","author":"Petereit DG","year":"1993","unstructured":"Petereit DG, Mehta MP, Buchler DA,  Inguinofemoral radiation of N0,N1 vulvar cancer may be equivalent to lymphadenectomy if proper radiation technique is used. Int J Radiat Oncol Biol Phys 1993;27:963\u2013967."},{"key":"B16","series-title":"Clin Obstet Gynecol","first-page":"869","article-title":"Surgery for vulvar cancer","volume":"48","author":"Rouzier R","year":"2005","unstructured":"Rouzier R, Haddad B, Atallah D,  Surgery for vulvar cancer. Clin Obstet Gynecol 2005;48:869\u2013878."},{"key":"B17","series-title":"Obstet Gynecol","first-page":"719","article-title":"Carcinoma of the vulva","volume":"107","author":"Stehman FB","year":"2006","unstructured":"Stehman FB, Look KY. Carcinoma of the vulva. Obstet Gynecol 2006;107:719\u2013733."},{"key":"B18","series-title":"Gynecol Oncol","first-page":"24","article-title":"Squamous cell carcinoma of the vulva stage IA: long-term results","volume":"76","author":"Magrina JF","year":"2000","unstructured":"Magrina JF, Gonzalez-Bosquet J, Weaver AL,  Squamous cell carcinoma of the vulva stage IA: long-term results. Gynecol Oncol 2000;76:24\u201327."},{"key":"B19","series-title":"Am J Surg Pathol","first-page":"765","article-title":"Stage IA vulvar squamous cell carcinoma: an analysis of tumor invasive characteristics and risk","volume":"32","author":"Yoder BJ","year":"2008","unstructured":"Yoder BJ, Rufforny I, Massoll NA,  Stage IA vulvar squamous cell carcinoma: an analysis of tumor invasive characteristics and risk. Am J Surg Pathol 2008;32:765\u2013772."},{"key":"B20","series-title":"Clin Obstet Gynecol","first-page":"188","article-title":"Superficial invasive carcinoma of the vulva","volume":"28","author":"Wilkinson EJ","year":"1985","unstructured":"Wilkinson EJ. Superficial invasive carcinoma of the vulva. Clin Obstet Gynecol 1985;28:188\u2013195."},{"key":"B21","series-title":"Gynecol Oncol","first-page":"155","article-title":"Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173","volume":"128","author":"Coleman RL","year":"2013","unstructured":"Coleman RL, Ali S, Levenback CF,  Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173. Gynecol Oncol 2013;128:155\u2013159."},{"key":"B22","series-title":"Ann Surg Oncol","first-page":"2508","article-title":"The risk of contralateral non-sentinel metastasis in patients with primary vulvar cancer and unilaterally positive sentinel node","volume":"23","author":"Woelber L","year":"2016","unstructured":"Woelber L, Eulenburg C, Grimm D,  The risk of contralateral non-sentinel metastasis in patients with primary vulvar cancer and unilaterally positive sentinel node. Ann Surg Oncol 2016;23:2508\u20132514."},{"key":"B23","series-title":"Gynecol Oncol","first-page":"3","article-title":"Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe","volume":"167","author":"Van der Kolk WL","year":"2022","unstructured":"Van der Kolk WL, Van der Zee AG, Slomovitz BM,  Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe. Gynecol Oncol 2022;167:3\u201310."},{"key":"B24","year":"1991","unstructured":"Greer BE, Berek JS, eds. Current Topics In Obstetrics And Gynecology: Gynecologic Oncology: Treatment Rationale And Techniques. Elsevier; 1991."},{"key":"B25","series-title":"Gynecol Oncol","first-page":"87","article-title":"Exenteration in the treatment of stage III\/IV vulvar cancer","volume":"124","author":"Forner DM","year":"2012","unstructured":"Forner DM, Lampe B. Exenteration in the treatment of stage III\/IV vulvar cancer. Gynecol Oncol 2012;124:87\u201391."},{"key":"B26","series-title":"Gynecol Oncol","first-page":"202","article-title":"Pelvic exenteration for primary and recurrent vulvar cancer","volume":"58","author":"Miller B","year":"1995","unstructured":"Miller B, Morris M, Levenback C,  Pelvic exenteration for primary and recurrent vulvar cancer. Gynecol Oncol 1995;58:202\u2013205."},{"key":"B27","series-title":"Int J Gynecol Cancer","first-page":"369","article-title":"Ultraradical surgery for advanced carcinoma of the vulva: an update","volume":"3","author":"Hoffman MS","year":"1993","unstructured":"Hoffman MS, Cavanagh D, Roberts WS,  Ultraradical surgery for advanced carcinoma of the vulva: an update. Int J Gynecol Cancer 1993;3:369\u2013372."},{"key":"B28","series-title":"Crit Rev Oncol Hematol","first-page":"227","article-title":"Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer","volume":"60","author":"Gadducci A","year":"2006","unstructured":"Gadducci A, Cionini L, Romanini A,  Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hematol 2006;60:227\u2013241."},{"key":"B29","series-title":"Cancer","first-page":"1085","article-title":"Combined therapy as an alternative to exenteration for locally advanced vulvo-vaginal cancer: rationale and results","volume":"49","author":"Boronow RC","year":"1982","unstructured":"Boronow RC. Combined therapy as an alternative to exenteration for locally advanced vulvo-vaginal cancer: rationale and results. Cancer 1982;49:1085\u20131091."},{"key":"B30","series-title":"Hematol Oncol Clin North Am","first-page":"45","article-title":"Current management of vulvar cancer","volume":"26","author":"Fuh KC","year":"2012","unstructured":"Fuh KC, Berek JS. Current management of vulvar cancer. Hematol Oncol Clin North Am 2012;26:45\u201362."},{"key":"B31","series-title":"Gynecol Oncol","first-page":"509","article-title":"Prophylactic chemoradiation of inguinofemoral lymph nodes in patients with locally extensive vulvar cancer","volume":"66","author":"Leiserowitz GS","year":"1997","unstructured":"Leiserowitz GS, Russell AH, Kinney WK,  Prophylactic chemoradiation of inguinofemoral lymph nodes in patients with locally extensive vulvar cancer. Gynecol Oncol 1997;66:509\u2013514."},{"key":"B32","series-title":"Gynecol Oncol","first-page":"14","article-title":"Synchronous radiation and cytotoxic chemotherapy for locally advanced or recurrent squamous cancer of the vulva","volume":"47","author":"Russell AH","year":"1992","unstructured":"Russell AH, Mesic JB, Scudder SA,  Synchronous radiation and cytotoxic chemotherapy for locally advanced or recurrent squamous cancer of the vulva. Gynecol Oncol 1992;47:14\u201320."},{"key":"B33","series-title":"Gynecol Oncol","first-page":"263","article-title":"Concurrent radiation and chemotherapy in vulvar carcinoma","volume":"34","author":"Thomas G","year":"1989","unstructured":"Thomas G, Dembo A, DePetrillo A,  Concurrent radiation and chemotherapy in vulvar carcinoma. Gynecol Oncol 1989;34:263\u2013267."},{"key":"B34","series-title":"Gynecol Oncol","first-page":"51","article-title":"Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally advanced carcinoma of the vulva","volume":"59","author":"Eifel PJ","year":"1995","unstructured":"Eifel PJ, Morris M, Burke TW,  Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally advanced carcinoma of the vulva. Gynecol Oncol 1995;59:51\u201356."},{"key":"B35","series-title":"Cancer","first-page":"1472","article-title":"Combined preoperative chemoradiotherapy followed by radical surgery in locally advanced vulvar carcinoma. A pilot study","volume":"77","author":"Lupi G","year":"1996","unstructured":"Lupi G, Raspagliesi F, Zucali R,  Combined preoperative chemoradiotherapy followed by radical surgery in locally advanced vulvar carcinoma. A pilot study. Cancer 1996;77:1472\u20131478."},{"key":"B36","series-title":"Int J Radiat Oncol Biol Phys","first-page":"79","article-title":"Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group","volume":"42","author":"Moore DH","year":"1998","unstructured":"Moore DH, Thomas GM, Montana GS,  Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. Int J Radiat Oncol Biol Phys 1998;42:79\u201385."},{"key":"B37","series-title":"Gynecol Oncol","first-page":"53","article-title":"Neoadjuvant chemotherapy in vulvar cancer: avoiding primary exenteration","volume":"100","author":"Geisler JP","year":"2006","unstructured":"Geisler JP, Manahan KJ, Buller RE. Neoadjuvant chemotherapy in vulvar cancer: avoiding primary exenteration. Gynecol Oncol 2006;100:53\u201357."},{"key":"B38","series-title":"Gynecol Oncol","first-page":"321","article-title":"Concurrent preoperative chemotherapy with 5-fluorouracil and mitomycin C and radiotherapy (FUMIR) followed by limited surgery in locally advanced and recurrent vulvar carcinoma","volume":"61","author":"Landoni F","year":"1996","unstructured":"Landoni F, Maneo A, Zanetta G,  Concurrent preoperative chemotherapy with 5-fluorouracil and mitomycin C and radiotherapy (FUMIR) followed by limited surgery in locally advanced and recurrent vulvar carcinoma. Gynecol Oncol 1996;61:321\u2013327."},{"key":"B39","series-title":"Gynecol Oncol","first-page":"197","article-title":"Concurrent cisplatin and 5-fluorouracil chemotherapy and radiation therapy for advanced-stage squamous carcinoma of the vulva","volume":"42","author":"Berek JS","year":"1991","unstructured":"Berek JS, Heaps JM, Fu YS,  Concurrent cisplatin and 5-fluorouracil chemotherapy and radiation therapy for advanced-stage squamous carcinoma of the vulva. Gynecol Oncol 1991;42:197\u2013201."},{"key":"B40","series-title":"Int J Radiat Oncol Biol Phys","first-page":"809","article-title":"Combined radiotherapy and chemotherapy in the management of local-regionally advanced vulvar cancer","volume":"26","author":"Koh WJ","year":"1993","unstructured":"Koh WJ, Wallace HJ 3rd, Greer BE,  Combined radiotherapy and chemotherapy in the management of local-regionally advanced vulvar cancer. Int J Radiat Oncol Biol Phys 1993;26:809\u2013816."},{"key":"B41","series-title":"Gynecol Oncol","first-page":"258","article-title":"Primary radiation, cisplatin, and 5-fluorouracil for advanced squamous carcinoma of the vulva","volume":"66","author":"Cunningham MJ","year":"1997","unstructured":"Cunningham MJ, Goyer RP, Gibbons SK,  Primary radiation, cisplatin, and 5-fluorouracil for advanced squamous carcinoma of the vulva. Gynecol Oncol 1997;66:258\u2013261."},{"key":"B42","series-title":"Gynecol Oncol","first-page":"640","article-title":"Preoperative chemoradiation for locally advanced carcinoma of the vulva","volume":"99","author":"Gerszten K","year":"2005","unstructured":"Gerszten K, Selvaraj RN, Kelley J,  Preoperative chemoradiation for locally advanced carcinoma of the vulva. Gynecol Oncol 2005;99:640\u2013644."},{"key":"B43","series-title":"Am J Clin Oncol","first-page":"22","article-title":"The role of chemo-radiotherapy in the management of locally advanced carcinoma of the vulva: single institutional experience and review of literature","volume":"34","author":"Tans L","year":"2011","unstructured":"Tans L, Ansink AC, van Rooij PH,  The role of chemo-radiotherapy in the management of locally advanced carcinoma of the vulva: single institutional experience and review of literature. Am J Clin Oncol 2011;34:22\u201326."},{"key":"B44","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1235","article-title":"Chemoradiation as primary or adjuvant treatment for locally advanced carcinoma of the vulva","volume":"47","author":"Han SC","year":"2000","unstructured":"Han SC, Kim DH, Higgins SA,  Chemoradiation as primary or adjuvant treatment for locally advanced carcinoma of the vulva. Int J Radiat Oncol Biol Phys 2000;47:1235\u20131244."},{"key":"B45","series-title":"Gynecol Oncol","first-page":"572","article-title":"Improved survival with definitive chemoradiation compared to definitive radiation alone in squamous cell carcinoma of the vulva: a review of the National Cancer Database","volume":"146","author":"Rao YJ","year":"2017","unstructured":"Rao YJ, Chin RI, Hui C,  Improved survival with definitive chemoradiation compared to definitive radiation alone in squamous cell carcinoma of the vulva: a review of the National Cancer Database. Gynecol Oncol 2017;146:572\u2013579."},{"key":"B46","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1007","article-title":"Preoperative chemo-radiation for carcinoma of the vulva with N2\/N3 nodes: a gynecologic oncology group study","volume":"48","author":"Montana GS","year":"2000","unstructured":"Montana GS, Thomas GM, Moore DH,  Preoperative chemo-radiation for carcinoma of the vulva with N2\/N3 nodes: a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 2000;48:1007\u20131013."},{"key":"B47","series-title":"Gynecol Oncol","first-page":"529","article-title":"A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study","volume":"124","author":"Moore DH","year":"2012","unstructured":"Moore DH, Ali S, Koh WJ,  A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study. Gynecol Oncol 2012;124:529\u2013533."},{"key":"B48","series-title":"Gynecol Oncol","first-page":"117","article-title":"Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: an efficacy study","volume":"163","author":"van Triest B","year":"2021","unstructured":"van Triest B, Rasing M, van der Velden J,  Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: an efficacy study. Gynecol Oncol 2021;163:117\u2013124."},{"key":"B49","series-title":"Int J Gynecol Cancer","first-page":"794","article-title":"Primary versus preoperative radiation for locally advanced vulvar cancer","volume":"27","author":"Natesan D","year":"2017","unstructured":"Natesan D, Hong JC, Foote J,  Primary versus preoperative radiation for locally advanced vulvar cancer. Int J Gynecol Cancer 2017;27:794\u2013804."},{"key":"B50","series-title":"Cochrane Database Syst Rev","first-page":"CD003752","article-title":"Chemoradiation for advanced primary vulval cancer","volume":"2011","author":"Shylasree TS","year":"2011","unstructured":"Shylasree TS, Bryant A, Howells RE. Chemoradiation for advanced primary vulval cancer. Cochrane Database Syst Rev 2011;2011:CD003752."},{"key":"B51","series-title":"Cochrane Database Syst Rev","first-page":"CD003752","article-title":"Neoadjuvant chemoradiation for advanced primary vulvar cancer","author":"van Doorn HC","year":"2006","unstructured":"van Doorn HC, Ansink A, Verhaar-Langereis M,  Neoadjuvant chemoradiation for advanced primary vulvar cancer. Cochrane Database Syst Rev 2006;2006:CD003752."},{"key":"B52","series-title":"Gynecol Oncol","first-page":"780","article-title":"Systemic therapy in squamous cell carcinoma of the vulva: current status and future directions","volume":"132","author":"Reade CJ","year":"2014","unstructured":"Reade CJ, Eiriksson LR, Mackay H. Systemic therapy in squamous cell carcinoma of the vulva: current status and future directions. Gynecol Oncol 2014;132:780\u2013789."},{"key":"B53","series-title":"Radiat Oncol","first-page":"15","article-title":"Radiosensitizers in cervical cancer. Cisplatin and beyond","volume":"1","author":"Candelaria M","year":"2006","unstructured":"Candelaria M, Garcia-Arias A, Cetina L,  Radiosensitizers in cervical cancer. Cisplatin and beyond. Radiat Oncol 2006;1:15."},{"key":"B54","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1226","article-title":"Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial","volume":"55","author":"Lorvidhaya V","year":"2003","unstructured":"Lorvidhaya V, Chitapanarux I, Sangruchi S,  Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial. Int J Radiat Oncol Biol Phys 2003;55:1226\u20131232."},{"key":"B55","series-title":"Eur J Gynaecol Oncol","first-page":"115","article-title":"Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix. A pilot study with intensification of dose","volume":"23","author":"Cerrotta A","year":"2002","unstructured":"Cerrotta A, Gardan G, Cavina R,  Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix. A pilot study with intensification of dose. Eur J Gynaecol Oncol 2002;23:115\u2013119."},{"key":"B56","series-title":"Gynecol Oncol","first-page":"404","article-title":"Phase II study of concurrent gemcitabine and radiotherapy in locally advanced stage IIIB cervical carcinoma","volume":"81","author":"Pattaranutaporn P","year":"2001","unstructured":"Pattaranutaporn P, Thirapakawong C, Chansilpa Y,  Phase II study of concurrent gemcitabine and radiotherapy in locally advanced stage IIIB cervical carcinoma. Gynecol Oncol 2001;81:404\u2013407."},{"key":"B57","series-title":"Int J Gynecol Cancer","first-page":"865","article-title":"Weekly paclitaxel\/carboplatin in the treatment of locally advanced, recurrent, or metastatic vulvar cancer","volume":"22","author":"Han SN","year":"2012","unstructured":"Han SN, Vergote I, Amant F. Weekly paclitaxel\/carboplatin in the treatment of locally advanced, recurrent, or metastatic vulvar cancer. Int J Gynecol Cancer 2012;22:865\u2013868."},{"key":"B58","series-title":"Ann Oncol","first-page":"1511","article-title":"Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer\u2014Gynaecological Cancer Group)","volume":"20","author":"Witteveen PO","year":"2009","unstructured":"Witteveen PO, van der Velden J, Vergote I,  Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer\u2014Gynaecological Cancer Group). Ann Oncol 2009;20:1511\u20131516."},{"key":"B59","series-title":"Gynecol Oncol","first-page":"141","article-title":"Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva","volume":"127","author":"Horowitz NS","year":"2012","unstructured":"Horowitz NS, Olawaiye AB, Borger DR,  Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. Gynecol Oncol 2012;127:141\u2013146."},{"key":"B60","series-title":"Oncology (Williston Park)","first-page":"867","article-title":"ACR Appropriateness Criteria adjuvant therapy in vulvar cancer","volume":"29","author":"Jolly S","year":"2015","unstructured":"Jolly S, Soni P, Gaffney DK,  ACR Appropriateness Criteria adjuvant therapy in vulvar cancer. Oncology (Williston Park) 2015;29:867\u2013872; 874\u2013865."},{"key":"B61","series-title":"Obstet Gynecol","first-page":"733","article-title":"Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes","volume":"68","author":"Homesley HD","year":"1986","unstructured":"Homesley HD, Bundy BN, Sedlis A,  Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. Obstet Gynecol 1986;68:733\u2013740."},{"key":"B62","series-title":"Obstet Gynecol","first-page":"537","article-title":"Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial","volume":"114","author":"Kunos C","year":"2009","unstructured":"Kunos C, Simpkins F, Gibbons H,  Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial. Obstet Gynecol 2009;114:537\u2013546."},{"key":"B63","series-title":"Gynecol Oncol","first-page":"87","article-title":"Challenges to delivery and effectiveness of adjuvant radiation therapy in elderly patients with node-positive vulvar cancer","volume":"146","author":"Swanick CW","year":"2017","unstructured":"Swanick CW, Eifel PJ, Huo J,  Challenges to delivery and effectiveness of adjuvant radiation therapy in elderly patients with node-positive vulvar cancer. Gynecol Oncol 2017;146:87\u201393."},{"key":"B64","series-title":"Gynecol Oncol","first-page":"343","article-title":"Adjuvant radiotherapy in patients with vulvar cancer and one intra capsular lymph node metastasis is not beneficial","volume":"114","author":"Fons G","year":"2009","unstructured":"Fons G, Groenen SM, Oonk MH,  Adjuvant radiotherapy in patients with vulvar cancer and one intra capsular lymph node metastasis is not beneficial. Gynecol Oncol 2009;114:343\u2013345."},{"key":"B65","series-title":"J Natl Cancer Inst","first-page":"dju426","article-title":"Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study","volume":"107","author":"Mahner S","year":"2015","unstructured":"Mahner S, Jueckstock J, Hilpert F,  Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. J Natl Cancer Inst 2015;107:dju426."},{"key":"B66","series-title":"Gynecol Oncol","first-page":"1095","article-title":"The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma","volume":"103","author":"Parthasarathy A","year":"2006","unstructured":"Parthasarathy A, Cheung MK, Osann K,  The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma. Gynecol Oncol 2006;103:1095\u20131099."},{"key":"B67","series-title":"Int J Gynecol Cancer","first-page":"503","article-title":"Prognostic role of lymph node metastases in vulvar cancer and implications for adjuvant treatment","volume":"22","author":"Woelber L","year":"2012","unstructured":"Woelber L, Eulenburg C, Choschzick M,  Prognostic role of lymph node metastases in vulvar cancer and implications for adjuvant treatment. Int J Gynecol Cancer 2012;22:503\u2013508."},{"key":"B68","series-title":"Gynecol Oncol","first-page":"365","article-title":"Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: a National Cancer Data Base (NCDB) analysis","volume":"137","author":"Gill BS","year":"2015","unstructured":"Gill BS, Bernard ME, Lin JF,  Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: a National Cancer Data Base (NCDB) analysis. Gynecol Oncol 2015;137:365\u2013372."},{"key":"B69","series-title":"Oncology (Williston Park)","article-title":"Delivery and outcomes of adjuvant radiation therapy in older women with node-positive vulvar cancer","volume":"30","author":"Swanick CW","year":"2016","unstructured":"Swanick CW, Smith GL, Huo J,  Delivery and outcomes of adjuvant radiation therapy in older women with node-positive vulvar cancer. Oncology (Williston Park) 2016;30(Suppl 1):Abstract P021."},{"key":"B70","series-title":"J Cancer Res Clin Oncol","first-page":"489","article-title":"Adjuvant radiotherapy for vulvar cancer with close or positive surgical margins","volume":"142","author":"Ignatov T","year":"2016","unstructured":"Ignatov T, Eggemann H, Burger E,  Adjuvant radiotherapy for vulvar cancer with close or positive surgical margins. J Cancer Res Clin Oncol 2016;142:489\u2013495."},{"key":"B71","series-title":"Gynecol Oncol","first-page":"545","article-title":"Relationship of margin status and radiation dose to recurrence in post-operative vulvar carcinoma","volume":"130","author":"Viswanathan AN","year":"2013","unstructured":"Viswanathan AN, Pinto AP, Schultz D,  Relationship of margin status and radiation dose to recurrence in post-operative vulvar carcinoma. Gynecol Oncol 2013;130:545\u2013549."},{"key":"B72","series-title":"J Clin Oncol","first-page":"884","article-title":"Sentinel node dissection is safe in the treatment of early-stage vulvar cancer","volume":"26","author":"Van der Zee AG","year":"2008","unstructured":"Van der Zee AG, Oonk MH, De Hullu JA,  Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol 2008;26:884\u2013889."},{"key":"B73","series-title":"Int J Gynecol Cancer","first-page":"773","article-title":"Lymph node count at inguinofemoral lymphadenectomy and groin recurrences in vulvar cancer","volume":"24","author":"van Beekhuizen HJ","year":"2014","unstructured":"van Beekhuizen HJ, Auzin M, van den Einden LC,  Lymph node count at inguinofemoral lymphadenectomy and groin recurrences in vulvar cancer. Int J Gynecol Cancer 2014;24:773\u2013778."},{"key":"B74","series-title":"Gynecol Oncol","first-page":"314","article-title":"Complete groin lymphadenectomy with preservation of the fascia lata in the treatment of vulvar carcinoma","volume":"77","author":"Bell JG","year":"2000","unstructured":"Bell JG, Lea JS, Reid GC. Complete groin lymphadenectomy with preservation of the fascia lata in the treatment of vulvar carcinoma. Gynecol Oncol 2000;77:314\u2013318."},{"key":"B75","series-title":"Obstet Gynecol","first-page":"490","article-title":"Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group","volume":"79","author":"Stehman FB","year":"1992","unstructured":"Stehman FB, Bundy BN, Dvoretsky PM,  Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group. Obstet Gynecol 1992;79:490\u2013497."},{"key":"B76","series-title":"Gynecol Oncol","first-page":"309","article-title":"Outcomes of stage I\/II vulvar cancer patients after negative superficial inguinal lymphadenectomy","volume":"98","author":"Kirby TO","year":"2005","unstructured":"Kirby TO, Rocconi RP, Numnum TM,  Outcomes of stage I\/II vulvar cancer patients after negative superficial inguinal lymphadenectomy. Gynecol Oncol 2005;98:309\u2013312."},{"key":"B77","series-title":"Gynecol Oncol","first-page":"828","article-title":"Long-term survival and disease recurrence in patients with primary squamous cell carcinoma of the vulva","volume":"97","author":"Gonzalez Bosquet J","year":"2005","unstructured":"Gonzalez Bosquet J, Magrina JF, Gaffey TA,  Long-term survival and disease recurrence in patients with primary squamous cell carcinoma of the vulva. Gynecol Oncol 2005;97:828\u2013833."},{"key":"B78","series-title":"Crit Rev Oncol Hematol","first-page":"1","article-title":"Risk factors and treatment for recurrent vulvar squamous cell carcinoma","volume":"106","author":"Nooij LS","year":"2016","unstructured":"Nooij LS, van den Brand FA, Gaarenstroom KN,  Risk factors and treatment for recurrent vulvar squamous cell carcinoma. Crit Rev Oncol Hematol 2016;106:1\u201313."},{"key":"B79","series-title":"Gynecol Oncol","first-page":"465","article-title":"Patient, tumor, and health system factors affecting groin node dissection rates in vulvar carcinoma: a population-based cohort study","volume":"139","author":"Gien LT","year":"2015","unstructured":"Gien LT, Sutradhar R, Thomas G,  Patient, tumor, and health system factors affecting groin node dissection rates in vulvar carcinoma: a population-based cohort study. Gynecol Oncol 2015;139:465\u2013470."},{"key":"B80","series-title":"Gynecol Oncol","first-page":"3","article-title":"An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations","volume":"146","author":"Salani R","year":"2017","unstructured":"Salani R, Khanna N, Frimer M,  An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 2017;146:3\u201310."},{"key":"B81","series-title":"Cancer","first-page":"116","article-title":"Patterns of recurrence in patients with squamous cell carcinoma of the vulva. A multicenter CTF Study","volume":"89","author":"Maggino T","year":"2000","unstructured":"Maggino T, Landoni F, Sartori E,  Patterns of recurrence in patients with squamous cell carcinoma of the vulva. A multicenter CTF Study. Cancer 2000;89:116\u2013122."},{"key":"B82","series-title":"Expert Rev Anticancer Ther","first-page":"629","article-title":"Systemic treatment of vulvar cancer","volume":"15","author":"Mahner S","year":"2015","unstructured":"Mahner S, Prieske K, Grimm D,  Systemic treatment of vulvar cancer. Expert Rev Anticancer Ther 2015;15:629\u2013637."},{"key":"B83","series-title":"Curr Treat Options Oncol","first-page":"143","article-title":"Recurrent vulvar cancer","volume":"3","author":"Salom EM","year":"2002","unstructured":"Salom EM, Penalver M. Recurrent vulvar cancer. Curr Treat Options Oncol 2002;3:143\u2013153."},{"key":"B84","series-title":"Gynecol Oncol","first-page":"189","article-title":"Recurrent squamous cell carcinoma of the vulva: a study of 73 cases","volume":"48","author":"Piura B","year":"1993","unstructured":"Piura B, Masotina A, Murdoch J,  Recurrent squamous cell carcinoma of the vulva: a study of 73 cases. Gynecol Oncol 1993;48:189\u2013195."},{"key":"B85","series-title":"Anticancer Res","first-page":"3105","article-title":"Radiotherapy alone and chemoirradiation in recurrent squamous cell carcinoma of the vulva","volume":"23","author":"Raffetto N","year":"2003","unstructured":"Raffetto N, Tombolini V, Santarelli M,  Radiotherapy alone and chemoirradiation in recurrent squamous cell carcinoma of the vulva. Anticancer Res 2003;23:3105\u20133108."},{"key":"B86","series-title":"Obstet Gynecol","first-page":"63","article-title":"Carcinoma of the vulva: analysis of treatment and survival","volume":"61","author":"Podratz KC","year":"1983","unstructured":"Podratz KC, Symmonds RE, Taylor WF,  Carcinoma of the vulva: analysis of treatment and survival. Obstet Gynecol 1983;61:63\u201374."},{"key":"B87","series-title":"Int J Gynecol Cancer","first-page":"156","article-title":"Morbidity after pelvic exenteration for gynecological malignancies: a retrospective multicentric study of 230 patients","volume":"24","author":"Chiantera V","year":"2014","unstructured":"Chiantera V, Rossi M, De Iaco P,  Morbidity after pelvic exenteration for gynecological malignancies: a retrospective multicentric study of 230 patients. Int J Gynecol Cancer 2014;24:156\u2013164."},{"key":"B88","series-title":"Am J Obstet Gynecol","first-page":"1128","article-title":"Sites of failure and times to failure in carcinoma of the vulva treated conservatively: a Gynecologic Oncology Group study","volume":"174","author":"Stehman FB","year":"1996","unstructured":"Stehman FB, Bundy BN, Ball H,  Sites of failure and times to failure in carcinoma of the vulva treated conservatively: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1996;174:1128\u20131132; discussion 1132\u20131133."},{"key":"B89","series-title":"Obstet Gynecol","first-page":"1001","article-title":"The surgical management of recurrent squamous cell carcinoma of the vulva","volume":"75","author":"Hopkins MP","year":"1990","unstructured":"Hopkins MP, Reid GC, Morley GW. The surgical management of recurrent squamous cell carcinoma of the vulva. Obstet Gynecol 1990;75:1001\u20131005."},{"key":"B90","series-title":"Gynecol Oncol","first-page":"227","article-title":"Single agent cisplatin chemotherapy in surgically resected vulvar cancer patients with multiple inguinal lymph node metastases","volume":"96","author":"Bellati F","year":"2005","unstructured":"Bellati F, Angioli R, Manci N,  Single agent cisplatin chemotherapy in surgically resected vulvar cancer patients with multiple inguinal lymph node metastases. Gynecol Oncol 2005;96:227\u2013231."},{"key":"B91","series-title":"Lancet","first-page":"1654","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari KS","year":"2017","unstructured":"Tewari KS, Sill MW, Penson RT,  Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 2017;390:1654\u20131663."},{"key":"B92","series-title":"Int J Gynecol Cancer","first-page":"1237","article-title":"Systematic review and network meta-analysis of bevacizumab plus first-line topotecan-paclitaxel or cisplatin-paclitaxel versus non-bevacizumab-containing therapies in persistent, recurrent, or metastatic cervical cancer","volume":"27","author":"Rosen VM","year":"2017","unstructured":"Rosen VM, Guerra I, McCormack M,  Systematic review and network meta-analysis of bevacizumab plus first-line topotecan-paclitaxel or cisplatin-paclitaxel versus non-bevacizumab-containing therapies in persistent, recurrent, or metastatic cervical cancer. Int J Gynecol Cancer 2017;27:1237\u20131246."},{"key":"B93","series-title":"J Clin Oncol","first-page":"2129","article-title":"Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505","volume":"33","author":"Kitagawa R","year":"2015","unstructured":"Kitagawa R, Katsumata N, Shibata T,  Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol 2015;33:2129\u20132135."},{"key":"B94","series-title":"Gynecol Oncol","first-page":"117","article-title":"A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer","volume":"133","author":"Lorusso D","year":"2014","unstructured":"Lorusso D, Petrelli F, Coinu A,  A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol Oncol 2014;133:117\u2013123."},{"key":"B95","series-title":"Eur J Gynaecol Oncol","first-page":"421","article-title":"Cisplatin-gemcitabine as palliative chemotherapy in advanced squamous vulvar carcinoma: report of two cases","volume":"33","author":"Santeufemia DA","year":"2012","unstructured":"Santeufemia DA, Capobianco G, Re GL,  Cisplatin-gemcitabine as palliative chemotherapy in advanced squamous vulvar carcinoma: report of two cases. Eur J Gynaecol Oncol 2012;33:421\u2013422."},{"key":"B96","series-title":"J Clin Oncol","first-page":"4649","article-title":"Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study","volume":"27","author":"Monk BJ","year":"2009","unstructured":"Monk BJ, Sill MW, McMeekin DS,  Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009;27:4649\u20134655."},{"key":"B97","series-title":"N Engl J Med","first-page":"341","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden MR","year":"2018","unstructured":"Migden MR, Rischin D, Schmults CD,  PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 2018;379:341\u2013351."},{"key":"B98","series-title":"N Engl J Med","first-page":"544","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari KS","year":"2022","unstructured":"Tewari KS, Monk BJ, Vergote I,  Survival with cemiplimab in recurrent cervical cancer. N Engl J Med 2022;386:544\u2013555."},{"key":"B99","series-title":"Am J Clin Oncol","first-page":"98","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder EI","year":"2016","unstructured":"Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 2016;39:98\u2013106."},{"key":"B100","series-title":"Clin Cancer Res","first-page":"6580","article-title":"Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1","volume":"18","author":"Chen DS","year":"2012","unstructured":"Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 2012;18:6580\u20136587."},{"key":"B101","series-title":"Nat Immunol","first-page":"492","article-title":"T cell exhaustion","volume":"12","author":"Wherry EJ","year":"2011","unstructured":"Wherry EJ. T cell exhaustion. Nat Immunol 2011;12:492\u2013499."},{"key":"B102","series-title":"Oncotarget","first-page":"92890","article-title":"Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology","volume":"8","author":"Hecking T","year":"2017","unstructured":"Hecking T, Thiesler T, Schiller C,  Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology. Oncotarget 2017;8:92890\u201392903."},{"key":"B103","series-title":"JAMA Oncol","first-page":"518","article-title":"Genetic basis for PD-L1 expression in squamous cell carcinomas of the cervix and vulva","volume":"2","author":"Howitt BE","year":"2016","unstructured":"Howitt BE, Sun HH, Roemer MG,  Genetic basis for PD-L1 expression in squamous cell carcinomas of the cervix and vulva. JAMA Oncol 2016;2:518\u2013522."},{"key":"B104","series-title":"J Immunother Cancer","first-page":"e000347","article-title":"Phase 2 study of pembrolizumab in patients with advanced rare cancers","volume":"8","author":"Naing A","year":"2020","unstructured":"Naing A, Meric-Bernstam F, Stephen B,  Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 2020;8:e000347."},{"key":"B105","series-title":"Sci Rep","first-page":"3667","article-title":"Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial","volume":"11","author":"How JA","year":"2021","unstructured":"How JA, Jazaeri AA, Soliman PT,  Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. Sci Rep 2021;11:3667."},{"key":"B106","series-title":"J Clin Oncol","first-page":"1470","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung HC","year":"2019","unstructured":"Chung HC, Ros W, Delord JP,  Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2019;37:1470\u20131478."},{"key":"B107","series-title":"Gynecol Oncol","first-page":"211","article-title":"Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study","volume":"166","author":"Shapira-Frommer R","year":"2022","unstructured":"Shapira-Frommer R, Mileshkin L, Manzyuk L,  Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study. Gynecol Oncol 2022;166:211\u2013218."},{"key":"B108","series-title":"Lancet Oncol","first-page":"1353","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle A","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J,  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21:1353\u20131365."},{"key":"B109","series-title":"J Clin Oncol","first-page":"1","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/ repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle A","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA,  Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/ repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:1\u201310."},{"key":"B110","unstructured":"US FDA. FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication. Accessed November 8, 2023. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication"},{"key":"B111","unstructured":"US FDA. FDA approves pembrolizumab for adults and children with TMB-H solid tumors. Accessed November 8, 2023. Available at: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors"},{"key":"B112","series-title":"J Clin Oncol","first-page":"2825","article-title":"Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I\/II CheckMate 358 trial","volume":"37","author":"Naumann RW","year":"2019","unstructured":"Naumann RW, Hollebecque A, Meyer T,  Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I\/II CheckMate 358 trial. J Clin Oncol 2019;37:2825\u20132834."},{"key":"B113","series-title":"Lancet Oncol","first-page":"271","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele RC","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L,  Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271\u2013282."},{"key":"B114","series-title":"N Engl J Med","first-page":"731","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon A","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S,  Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731\u2013739."},{"key":"B115","series-title":"Ann Oncol","first-page":"325","article-title":"Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study","volume":"30","author":"Hong DS","year":"2019","unstructured":"Hong DS, Bauer TM, Lee JJ,  Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol 2019;30:325\u2013331."},{"key":"B116","series-title":"Lancet Oncol","first-page":"531","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong DS","year":"2020","unstructured":"Hong DS, DuBois SG, Kummar S,  Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol 2020;21:531\u2013540."},{"key":"B117","series-title":"Int J Gynecol Cancer","first-page":"252","article-title":"Lower extremity lymphedema in patients with gynecologic malignancies","volume":"30","author":"Dessources K","year":"2020","unstructured":"Dessources K, Aviki E, Leitao MM Jr. Lower extremity lymphedema in patients with gynecologic malignancies. Int J Gynecol Cancer 2020;30:252\u2013260."},{"key":"B118","series-title":"Int J Gynecol Cancer","first-page":"1697","article-title":"Incidence, prevalence, and factors associated with lymphedema after treatment for cervical cancer: a systematic review","volume":"30","author":"Bona AF","year":"2020","unstructured":"Bona AF, Ferreira KR, Carvalho RBM,  Incidence, prevalence, and factors associated with lymphedema after treatment for cervical cancer: a systematic review. Int J Gynecol Cancer 2020;30:1697\u20131704."},{"key":"B119","series-title":"J Clin Oncol","first-page":"3325","article-title":"Prevention and management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline update","volume":"38","author":"Loprinzi CL","year":"2020","unstructured":"Loprinzi CL, Lacchetti C, Bleeker J,  Prevention and management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline update. J Clin Oncol 2020;38:3325\u20133348."},{"key":"B120","series-title":"Support Care Cancer","first-page":"1425","article-title":"Extended duration of dilator use beyond 1 year may reduce vaginal stenosis after intravaginal high-dose-rate brachytherapy","volume":"27","author":"Stahl JM","year":"2019","unstructured":"Stahl JM, Qian JM, Tien CJ,  Extended duration of dilator use beyond 1 year may reduce vaginal stenosis after intravaginal high-dose-rate brachytherapy. Support Care Cancer 2019;27:1425\u20131433."},{"key":"B121","series-title":"Brachytherapy","first-page":"464","article-title":"Predictors of vaginal stenosis after intravaginal high-dose-rate brachytherapy for endometrial carcinoma","volume":"14","author":"Park HS","year":"2015","unstructured":"Park HS, Ratner ES, Lucarelli L,  Predictors of vaginal stenosis after intravaginal high-dose-rate brachytherapy for endometrial carcinoma. Brachytherapy 2015;14:464\u2013470."},{"key":"B122","series-title":"Radiat Oncol J","first-page":"85","article-title":"Radiation induced secondary malignancies: a review article","volume":"36","author":"Dracham CB","year":"2018","unstructured":"Dracham CB, Shankar A, Madan R. Radiation induced secondary malignancies: a review article. Radiat Oncol J 2018;36:85\u201394."},{"key":"B123","series-title":"Int J Mol Sci","first-page":"190","article-title":"Is there a place for immune checkpoint inhibitors in vulvar neoplasms? A state of the art review","volume":"22","author":"Borella F","year":"2020","unstructured":"Borella F, Preti M, Bertero L,  Is there a place for immune checkpoint inhibitors in vulvar neoplasms? A state of the art review. Int J Mol Sci 2020;22:190."},{"key":"B124","series-title":"Cancers (Basel)","first-page":"840","article-title":"Immunotherapy and its development for gynecological (ovarian, endometrial and cervical) tumors: from immune checkpoint inhibitors to chimeric antigen receptor (CAR)-T cell therapy","volume":"13","author":"Schepisi G","year":"2021","unstructured":"Schepisi G, Casadei C, Toma I,  Immunotherapy and its development for gynecological (ovarian, endometrial and cervical) tumors: from immune checkpoint inhibitors to chimeric antigen receptor (CAR)-T cell therapy. Cancers (Basel) 2021;13:840."},{"key":"B125","series-title":"Physiotherapy","first-page":"309","article-title":"Exercise interventions for patients with gynaecological cancer: a systematic review and meta-analysis","volume":"102","author":"Lin KY","year":"2016","unstructured":"Lin KY, Frawley HC, Denehy L,  Exercise interventions for patients with gynaecological cancer: a systematic review and meta-analysis. Physiotherapy 2016;102:309\u2013319."},{"key":"B126","series-title":"J Natl Cancer Inst","first-page":"1120","article-title":"Developing a quality of cancer survivorship care framework: implications for clinical care, research, and policy","volume":"111","author":"Nekhlyudov L","year":"2019","unstructured":"Nekhlyudov L, Mollica MA, Jacobsen PB,  Developing a quality of cancer survivorship care framework: implications for clinical care, research, and policy. J Natl Cancer Inst 2019;111:1120\u20131130."},{"key":"B127","series-title":"Curr Opin Support Palliat Care","first-page":"44","article-title":"How to ask and what to do: a guide for clinical inquiry and intervention regarding female sexual health after cancer","volume":"10","author":"Bober SL","year":"2016","unstructured":"Bober SL, Reese JB, Barbera L,  How to ask and what to do: a guide for clinical inquiry and intervention regarding female sexual health after cancer. Curr Opin Support Palliat Care 2016;10:44\u201354. https:\/\/journals.lww.com\/co-supportiveandpalliativecare\/Fulltext\/2016\/03000\/How_to_ask_and_what_to_do__a_guide_for_clinical.12.aspx"},{"key":"B128","series-title":"Pract Radiat Oncol","first-page":"479","article-title":"Literature review of vaginal stenosis and dilator use in radiation oncology","volume":"9","author":"Damast S","year":"2019","unstructured":"Damast S, Jeffery DD, Son CH,  Literature review of vaginal stenosis and dilator use in radiation oncology. Pract Radiat Oncol 2019;9:479\u2013491."},{"key":"B129","series-title":"Semin Oncol Nurs","first-page":"192","article-title":"Caring for survivors of gynecologic cancer: assessment and management of long-term and late effects","volume":"35","author":"Campbell G","year":"2019","unstructured":"Campbell G, Thomas TH, Hand L,  Caring for survivors of gynecologic cancer: assessment and management of long-term and late effects. Semin Oncol Nurs 2019;35:192\u2013201."},{"key":"B130","unstructured":"Society of Gynecologic Oncology. Survivorship toolkit. Accessed November 8, 2023. Available at: https:\/\/www.sgo.org\/resources\/survivorship-toolkit\/"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/2\/article-p117.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/2\/article-p117.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/2\/article-p117.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T15:35:09Z","timestamp":1710776109000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/2\/article-p117.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":130,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2024.0013","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}